Rising Diabetes Prevalence Provides Strong Growth Opportunities


BMI View: The rising diabetes prevalence in China, coupled with the at-present significant unmet treatment, means there are strong opportunities for pharmaceutical firms focusing on diabetes care in China. However, we highlight that accessibility to healthcare services and treatment options will be a key obstacle to pharmaceutical firms looking to maximize this commercial potential

According to a study published in the Journal of the American Medical Association (JAMA), researchers have estimated that 11.6% of China's population, or 113.9mn people, are diabetic (based on approximately 99,000 samples taken in 2010), which is the highest prevalence for a country globally. This figure was higher than the estimate given by a study in the New England Journal of Medicine (92mn) in 2010, [1] indicating rising commercial potential. Some key findings from the JAMA study include:

  • Prevalence among men was 12.1% and women was 11.0%;

  • Novo Nordisk: A Dominant Player
    Chinese Insulin Volume Market Share Of The Top Five Companies (May 2013)

or Register now for free to read the full article

This article is tagged to:
Sector: Pharmaceuticals & Healthcare, Infrastructure
Geography: China, China, China, China